CJC-1295 + GHRP-6 Stack vs PEG-MGF
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CJC-1295 + GHRP-6 Stack
CJC-1295 (GHRH analog) combined with GHRP-6 (potent ghrelin receptor agonist) to produce synergistic GH release via complementary mechanisms. GHRP-6's strong appetite stimulation distinguishes this from the CJC-1295 + Ipamorelin stack, making it preferred for bulking and mass-gaining protocols where caloric surplus is the goal. Produces larger GH pulses than CJC + Ipamorelin but with more pronounced appetite effects.
Full profilePEG-MGF
PEG-MGF is Mechano Growth Factor (MGF) conjugated to a polyethylene glycol (PEG) polymer chain. The PEGylation dramatically extends the half-life from ~5 minutes (native MGF) to approximately 24–72 hours, allowing less frequent dosing and systemic distribution rather than purely local action. This trade-off — longer duration vs localized intensity — makes PEG-MGF a different tool than native MGF, better suited for systemic muscle recovery support and convenience-focused protocols.
Full profile| CJC-1295 + GHRP-6 Stack | PEG-MGF | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | CJC GHRP-6 combination, GH releasing stack, GHRH GHRP combination, CJC-1295 GHRP-6 | PEGylated Mechano Growth Factor, Polyethylene Glycol-MGF, Long-acting MGF |
| Evidence | Research-stage | Preclinical only |
| Dosing range | CJC-1295 100mcg + GHRP-6 100mcg–CJC-1295 200mcg + GHRP-6 300mcg mcg, 1–3x daily (pre-sleep, pre-workout, morning) | 100mcg–400mcg mcg, 2x weekly (Monday/Thursday or similar split) |
| Administration | Subcutaneous injection | Subcutaneous injection (preferred for systemic distribution), Intramuscular injection |
| Key side effects | Strong appetite stimulation (GHRP-6 dominant effect), Water retention, Tingling / numbness in extremities, Mild cortisol elevation (GHRP-6 is less selective than ipamorelin) | Hypoglycemia (less pronounced than IGF-1 DES, more than native MGF due to systemic distribution), Generalized fatigue on injection days, PEG accumulation concern with very high doses over long periods (theoretical — not established at research doses), Localized injection site swelling |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: CJC-1295 + GHRP-6 Stack is research-stage, while PEG-MGF is preclinical only.
- Administration: CJC-1295 + GHRP-6 Stack — Subcutaneous injection; PEG-MGF — Subcutaneous injection (preferred for systemic distribution), Intramuscular injection.
- Frequency: CJC-1295 + GHRP-6 Stack is typically 1–3x daily (pre-sleep, pre-workout, morning); PEG-MGF is 2x weekly (Monday/Thursday or similar split).
How each works
CJC-1295 + GHRP-6 Stack
The GHRH + GHRP combination synergistically amplifies GH pulse amplitude compared to either agent alone. CJC-1295 elevates baseline GH via GHRH receptor signaling at the pituitary; GHRP-6 triggers pulse timing via GHS-R1a. GHRP-6's potent appetite stimulation (significantly stronger than ipamorelin) makes this combination preferred in protocols targeting caloric surplus and mass accumulation.
PEG-MGF
PEGylation is a validated pharmaceutical strategy for extending peptide half-life (used in Pegasys/interferon, Somavert/pegvisomant, and others). The PEG chain shields the MGF peptide from proteolytic degradation and slows renal clearance. Research in rodent models confirms PEG-MGF preserves the biological activity of native MGF (satellite cell activation, muscle repair) with extended duration. Unlike native MGF which requires precise post-workout injection timing, PEG-MGF can be injected on a scheduled basis and still achieves systemic muscle-wide satellite cell effects.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.